NSG BioLabs and Merck Collaborates to Support Biotech Start-ups to Advance Research & Innovations

August 15, 2024 03:00 AM BST | By Cision
 NSG BioLabs and Merck Collaborates to Support Biotech Start-ups to Advance Research & Innovations
Image source: Kalkine Media
  • The collaboration focuses on offering guidance, mentorship, and access to expertise to the start-ups housed within NSG Biolabs

SINGAPORE, Aug. 15, 2024 /PRNewswire/ -- NSG BioLabs, Singapore's largest provider of biotech co-working laboratory and office space, and the Life Science business of  Merck Singapore, announce partnership giving biotech start-ups access to resources and expertise to bolster the research and development capabilities of NSG Biolabs' tenants, thereby facilitating opportunities for funding, partnerships, production, and commercialization.

NSG BioLabs and Merck Collaborates to Support Biotech Start-ups to Advance Research & Innovation. The collaboration focuses on offering guidance, mentorship, and access to expertise to the start- ups housed within NSG Biolabs
NSG BioLabs and Merck Collaborates to Support Biotech Start-ups to Advance Research & Innovation. The collaboration focuses on offering guidance, mentorship, and access to expertise to the start- ups housed within NSG Biolabs

Since 2019, NSG BioLabs has been assisting innovators in creating impactful solutions in the health, biomedical, agrifood, and industrial biotechnology sectors, working in areas such as precision medicine, nucleic acids, AI-enabled drug discovery, synthetic biology, and other areas. With the largest co-working biotech laboratory and office footprint in Singapore, coupled with extensive networks with local and international partners, suppliers, and industry experts, NSG BioLabs has helped over 40 companies as residents. The company's residents include several multi-billion-dollar multinationals as well as many promising startups that have achieved key milestones. The startup residents alone have successfully raised nearly US$400 million in funding and supported hundreds of jobs.

"We are excited to announce this collaboration with Merck Singapore. At NSG BioLabs, our foremost commitment is creating an environment where our residents can flourish. This partnership will grant our residents exclusive access to Merck's scientists and engineers, state-of-the-art equipment, consumables, and services, enabling them to advance their research and expand their innovations. Together, we are forging the future of life sciences and catalyzing significant discoveries," said Daphne Teo, CEO and Founder of NSG BioLabs.

Speaking on the collaboration, Chua Keng Hock, Managing Director of Merck Singapore, and Senior Vice President of Process Solutions for APAC said, "Merck Singapore's partnership with NSG Biolabs underscores our commitment to supporting the growth and development of the biotech community in Singapore and across Asia Pacific. Merck offers one of the broadest portfolios in the industry for research discovery to pharmaceutical development and testing, and manufacturing of traditional and novel modalities, and access to the M Lab™ Collaboration Center in Singapore for off-site trial support and training on large equipment in a GMP-like environment."

Since its inception, NSG BioLabs has been supporting biotech startups and multinational companies by providing BSL-2 certified private and shared laboratory spaces and offices, equipment, privileged access with service providers and suppliers, and community engagement. After its first site opening in November 2019, NSG BioLabs expanded with its second site in August 2021, and recently in 2023 with its third site. Now, with three sites totaling 35,000 square feet located in the heart of Singapore's R&D ecosystem, NSG BioLabs cements its space as a key hub for biotech innovation. As one of the largest private biotech incubators in the region, coupled with its strong partnerships and strategic investors, such as Celadon Partners and ClavystBio, a life sciences investor set up by Temasek, NSG BioLabs is poised to enhance its value-add offerings of infrastructure, services, and networks for its growing community.

About NSG BioLabs

Founded with a focus on supporting biotech innovation, NSG BioLabs offers state-of-the-art equipment, efficient operations, capital efficiency, the expertise of world-class teams and global networks to assist life sciences companies. The conducive R&D environment contains fully-equipped, certified BSL-2 laboratory and office infrastructure across 35,000 sq ft in the prime location of Biopolis in Singapore. 

By providing access to high-quality infrastructure, its extensive partner network, community, and value-add benefits, NSG BioLabs ensures that companies, ranging from emerging biotech startups to multinational companies, can rapidly and efficiently execute on their cutting-edge research and development ecosystem in Singapore, leading to the innovation of revolutionary technologies and products that translate into breakthrough biotech ventures and impact for patients.

For more information, visit www.nsgbio.com


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AI on the Rise: A Look at Top AI Companies and Their Stocks

Send OTP Resend OTP in 30s
Verify OTP

Sponsored Articles


Investing Ideas

Previous Next